Drugs that contain Ibrutinib
1. List of Imbruvica drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7514444 | PHARMACYCLICS INC | Inhibitors of bruton's tyrosine kinase |
Dec, 2026
(3 years from now) | |
| US8957079 | PHARMACYCLICS INC | Inhibitors of Bruton's tyrosine kinase |
Dec, 2026
(3 years from now) | |
| US8735403 | PHARMACYCLICS INC | Inhibitors of Bruton's tyrosine kinase |
Dec, 2026
(3 years from now) | |
| US9181257 | PHARMACYCLICS INC | Inhibitors of Bruton's tyrosine kinase |
Dec, 2026
(3 years from now) | |
| US8697711 | PHARMACYCLICS INC | Inhibitors of bruton'S tyrosine kinase |
Dec, 2026
(3 years from now) | |
| US8008309 | PHARMACYCLICS INC | Inhibitors of bruton's tyrosine kinase |
Nov, 2027
(4 years from now) | |
| US9725455 | PHARMACYCLICS INC | Crystalline forms of a bruton's tyrosine kinase inhibitor |
Jun, 2033
(10 years from now) | |
| US10125140 | PHARMACYCLICS INC | Crystalline forms of a bruton's tyrosine kinase inhibitor |
Jun, 2033
(10 years from now) | |
| US10106548 | PHARMACYCLICS INC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Jun, 2033
(10 years from now) | |
| US9296753 | PHARMACYCLICS INC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Oct, 2033
(10 years from now) | |
| CN103319488A | PHARMACYCLICS INC | A Bruton ' S Tyrosine Kinase Inhibitor |
Nov, 2016
(6 years ago) | |
| CN104736178A | PHARMACYCLICS INC | Crystalline Form Of Bruton Tyrosine Kinase Inhibitor |
Jan, 2020
(3 years ago) | |
| CN102887900B | PHARMACYCLICS INC | Inhibitor Of Bruton ' S Tyrosine Kinase |
Dec, 2026
(3 years from now) | |
| CN101805341B | PHARMACYCLICS INC | Inhibitors Of Bruton'S Tyrosine Kinase |
Dec, 2026
(3 years from now) | |
| CN102746305B | PHARMACYCLICS INC | Inhibitor Of Bruton ' S Tyrosine Kinase |
Dec, 2026
(3 years from now) | |
| CN101805341A | PHARMACYCLICS INC | Inhibitors Of Bruton'S Tyrosine Kinase |
Dec, 2026
(3 years from now) | |
| CN101610676B | PHARMACYCLICS INC | Inhibitor Of Bruton Tyrosine Kinase |
Dec, 2026
(3 years from now) | |
| CN101610676A | PHARMACYCLICS INC | Inhibitors Of Bruton'S Tyrosine Kinase |
Dec, 2026
(3 years from now) | |
| CN102887900A | PHARMACYCLICS INC | Inhibitors Of Bruton'S Tyrosine Kinase |
Dec, 2026
(3 years from now) | |
| CN102746305A | PHARMACYCLICS INC | Inhibitors Of Bruton'S Tyrosine Kinase |
Dec, 2026
(3 years from now) | |
| CN101674834A | PHARMACYCLICS INC | A Bruton ' S Tyrosine Kinase (Bruton ' S Tyrosine Kinase Inhibitor |
Mar, 2028
(5 years from now) | |
| CN101674834B | PHARMACYCLICS INC | Inhibitors Of Bruton'S Tyrosine Kinase |
Mar, 2028
(5 years from now) | |
| IN201205631P1 | PHARMACYCLICS INC | Inhibitors Of Bruton'S Tyrosine Kinase |
Dec, 2026
(3 years from now) | |
| IN362133B | PHARMACYCLICS INC | Inhibitors Of Bruton&Amp;Apos;S Tyrosine Kinase |
Dec, 2026
(3 years from now) | |
| IN200901642P1 | PHARMACYCLICS INC | Inhibitors Of Bruton'S Tyrosine Kinase |
Mar, 2029
(6 years from now) | |
| EP2529622B1 | PHARMACYCLICS INC | Inhibitors Of Bruton'S Tyrosine Kinase |
Feb, 2019
(3 years ago) | |
| EP2529622A1 | PHARMACYCLICS INC | Inhibitors Of Bruton'S Tyrosine Kinase |
Feb, 2019
(3 years ago) | |
| EP2201840B1 | PHARMACYCLICS INC | Inhibitors Of Bruton'S Tyrosine Kinase |
Jul, 2020
(2 years ago) | |
| EP2201840A1 | PHARMACYCLICS INC | Inhibitors Of Bruton'S Tyrosine Kinase |
Jul, 2020
(2 years ago) | |
| EP2530083A1 | PHARMACYCLICS INC | Inhibitors Of Bruton'S Tyrosine Kinase |
Dec, 2026
(3 years from now) | |
| EP2081435A2 | PHARMACYCLICS INC | Inhibitors Of Bruton'S Tyrosine Kinase |
Dec, 2026
(3 years from now) | |
| EP2081435A4 | PHARMACYCLICS INC | Inhibitors Of Bruton'S Tyrosine Kinase |
Dec, 2026
(3 years from now) | |
| EP2526771A1 | PHARMACYCLICS INC | Inhibitors Of Bruton'S Tyrosine Kinase |
Dec, 2026
(3 years from now) | |
| EP2081435B1 | PHARMACYCLICS INC | Inhibitors Of Bruton'S Tyrosine Kinase |
Dec, 2026
(3 years from now) | |
| EP2526933B1 | PHARMACYCLICS INC | Inhibitors Of Bruton'S Tyrosine Kinase |
Dec, 2026
(3 years from now) | |
| EP2526771B1 | PHARMACYCLICS INC | Inhibitors Of Bruton'S Tyrosine Kinase |
Dec, 2026
(3 years from now) | |
| EP2530083B1 | PHARMACYCLICS INC | Inhibitors Of Bruton'S Tyrosine Kinase |
Dec, 2026
(3 years from now) | |
| EP2526933A3 | PHARMACYCLICS INC | Inhibitors Of Bruton'S Tyrosine Kinase |
Dec, 2026
(3 years from now) | |
| EP2526933A2 | PHARMACYCLICS INC | Inhibitors Of Bruton'S Tyrosine Kinase |
Dec, 2026
(3 years from now) | |
| EP2526934A3 | PHARMACYCLICS INC | Inhibitors Of Bruton'S Tyrosine Kinase |
Dec, 2026
(3 years from now) | |
| EP2529621A1 | PHARMACYCLICS INC | Inhibitors Of Bruton'S Tyrosine Kinase |
Dec, 2026
(3 years from now) | |
| EP2526934B1 | PHARMACYCLICS INC | Inhibitors Of Bruton'S Tyrosine Kinase |
Dec, 2026
(3 years from now) | |
| EP2529621B1 | PHARMACYCLICS INC | Inhibitors Of Bruton'S Tyrosine Kinase |
Dec, 2026
(3 years from now) | |
| EP2526934A2 | PHARMACYCLICS INC | Inhibitors Of Bruton'S Tyrosine Kinase |
Dec, 2026
(3 years from now) | |
| EP2139487A2 | PHARMACYCLICS INC | Inhibitors Of Bruton'S Tyrosine Kinase |
Mar, 2028
(5 years from now) | |
| EP2139487B1 | PHARMACYCLICS INC | Inhibitors Of Bruton'S Tyrosine Kinase |
Mar, 2028
(5 years from now) | |
| EP2139487A4 | PHARMACYCLICS INC | Inhibitors Of Bruton'S Tyrosine Kinase |
Mar, 2028
(5 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8952015 | PHARMACYCLICS INC | Inhibitors of Bruton's tyrosine kinase |
Dec, 2026
(3 years from now) | |
| US8754091 | PHARMACYCLICS INC | Inhibitors of bruton's tyrosine kinase |
Dec, 2026
(3 years from now) | |
| US8497277 | PHARMACYCLICS INC | Inhibitors of Bruton's tyrosine kinase |
Dec, 2026
(3 years from now) | |
| US8476284 | PHARMACYCLICS INC | Inhibitors of Bruton's tyrosine kinase |
Dec, 2026
(3 years from now) | |
| US8703780 | PHARMACYCLICS INC | Inhibitors of Bruton's tyrosine kinase |
Dec, 2026
(3 years from now) | |
| US8563563 | PHARMACYCLICS INC | Inhibitors of bruton's tyrosine kinase |
Apr, 2027
(4 years from now) | |
|
US8476284
(Pediatric) | PHARMACYCLICS INC | Inhibitors of Bruton's tyrosine kinase |
Jun, 2027
(4 years from now) | |
|
US8703780
(Pediatric) | PHARMACYCLICS INC | Inhibitors of Bruton's tyrosine kinase |
Jun, 2027
(4 years from now) | |
|
US8497277
(Pediatric) | PHARMACYCLICS INC | Inhibitors of Bruton's tyrosine kinase |
Jun, 2027
(4 years from now) | |
|
US7514444
(Pediatric) | PHARMACYCLICS INC | Inhibitors of bruton's tyrosine kinase |
Jun, 2027
(4 years from now) | |
|
US9181257
(Pediatric) | PHARMACYCLICS INC | Inhibitors of Bruton's tyrosine kinase |
Jun, 2027
(4 years from now) | |
|
US8735403
(Pediatric) | PHARMACYCLICS INC | Inhibitors of Bruton's tyrosine kinase |
Jun, 2027
(4 years from now) | |
|
US8697711
(Pediatric) | PHARMACYCLICS INC | Inhibitors of bruton'S tyrosine kinase |
Jun, 2027
(4 years from now) | |
|
US8754091
(Pediatric) | PHARMACYCLICS INC | Inhibitors of bruton's tyrosine kinase |
Jun, 2027
(4 years from now) | |
|
US8952015
(Pediatric) | PHARMACYCLICS INC | Inhibitors of Bruton's tyrosine kinase |
Jun, 2027
(4 years from now) | |
|
US8957079
(Pediatric) | PHARMACYCLICS INC | Inhibitors of Bruton's tyrosine kinase |
Jun, 2027
(4 years from now) | |
|
US8563563
(Pediatric) | PHARMACYCLICS INC | Inhibitors of bruton's tyrosine kinase |
Oct, 2027
(4 years from now) | |
|
US8008309
(Pediatric) | PHARMACYCLICS INC | Inhibitors of bruton's tyrosine kinase |
May, 2028
(5 years from now) | |
| US9814721 | PHARMACYCLICS INC | Use of inhibitors of bruton'S tyrosine kinase (BTK) |
Jun, 2031
(8 years from now) | |
| US10016435 | PHARMACYCLICS INC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Jun, 2031
(8 years from now) | |
| US8754090 | PHARMACYCLICS INC | Use of inhibitors of bruton's tyrosine kinase (Btk) |
Jun, 2031
(8 years from now) | |
| US10478439 | PHARMACYCLICS INC | Use of inhibitors of bruton's tyrosine kinase (Btk) |
Jun, 2031
(8 years from now) | |
| US10751342 | PHARMACYCLICS INC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Jun, 2031
(8 years from now) | |
| US10653696 | PHARMACYCLICS INC | Use of inhibitors of bruton's tyrosine kinase (BTK) |
Jun, 2031
(8 years from now) | |
| US10004746 | PHARMACYCLICS INC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Jun, 2031
(8 years from now) | |
| US9801883 | PHARMACYCLICS INC | Use of inhibitors of bruton's tyrosine kinase (Btk) |
Jun, 2031
(8 years from now) | |
| US9801881 | PHARMACYCLICS INC | Use of inhibitors of bruton's tyrosine kinase (BTK) |
Jun, 2031
(8 years from now) | |
| US9125889 | PHARMACYCLICS INC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Jun, 2031
(8 years from now) | |
| US8999999 | PHARMACYCLICS INC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Jun, 2031
(8 years from now) | |
|
US8754090
(Pediatric) | PHARMACYCLICS INC | Use of inhibitors of bruton's tyrosine kinase (Btk) |
Dec, 2031
(8 years from now) | |
|
US9801883
(Pediatric) | PHARMACYCLICS INC | Use of inhibitors of bruton's tyrosine kinase (Btk) |
Dec, 2031
(8 years from now) | |
|
US8999999
(Pediatric) | PHARMACYCLICS INC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Dec, 2031
(8 years from now) | |
|
US10016435
(Pediatric) | PHARMACYCLICS INC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Dec, 2031
(8 years from now) | |
|
US9125889
(Pediatric) | PHARMACYCLICS INC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Dec, 2031
(8 years from now) | |
|
US10478439
(Pediatric) | PHARMACYCLICS INC | Use of inhibitors of bruton's tyrosine kinase (Btk) |
Dec, 2031
(8 years from now) | |
|
US10653696
(Pediatric) | PHARMACYCLICS INC | Use of inhibitors of bruton's tyrosine kinase (BTK) |
Dec, 2031
(8 years from now) | |
|
US9801881
(Pediatric) | PHARMACYCLICS INC | Use of inhibitors of bruton's tyrosine kinase (BTK) |
Dec, 2031
(8 years from now) | |
|
US10004746
(Pediatric) | PHARMACYCLICS INC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Dec, 2031
(8 years from now) | |
|
US9814721
(Pediatric) | PHARMACYCLICS INC | Use of inhibitors of bruton'S tyrosine kinase (BTK) |
Dec, 2031
(8 years from now) | |
|
US10751342
(Pediatric) | PHARMACYCLICS INC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Dec, 2031
(8 years from now) | |
| US10961251 | PHARMACYCLICS INC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Jun, 2033
(10 years from now) | |
| US10294232 | PHARMACYCLICS INC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Jun, 2033
(10 years from now) | |
| US9713617 | PHARMACYCLICS INC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Jun, 2033
(10 years from now) | |
| US10294231 | PHARMACYCLICS INC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Jun, 2033
(10 years from now) | |
| US10752634 | PHARMACYCLICS INC | Crystalline forms of a brutons tyrosine kinase inhibitor |
Jun, 2033
(10 years from now) | |
| US9540382 | PHARMACYCLICS INC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Aug, 2033
(10 years from now) | |
|
US10961251
(Pediatric) | PHARMACYCLICS INC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Dec, 2033
(10 years from now) | |
|
US10294232
(Pediatric) | PHARMACYCLICS INC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Dec, 2033
(10 years from now) | |
|
US10294231
(Pediatric) | PHARMACYCLICS INC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Dec, 2033
(10 years from now) | |
|
US10125140
(Pediatric) | PHARMACYCLICS INC | Crystalline forms of a bruton's tyrosine kinase inhibitor |
Dec, 2033
(10 years from now) | |
|
US10106548
(Pediatric) | PHARMACYCLICS INC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Dec, 2033
(10 years from now) | |
|
US9725455
(Pediatric) | PHARMACYCLICS INC | Crystalline forms of a bruton's tyrosine kinase inhibitor |
Dec, 2033
(10 years from now) | |
|
US9713617
(Pediatric) | PHARMACYCLICS INC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Dec, 2033
(10 years from now) | |
|
US10752634
(Pediatric) | PHARMACYCLICS INC | Crystalline forms of a brutons tyrosine kinase inhibitor |
Dec, 2033
(10 years from now) | |
|
US9540382
(Pediatric) | PHARMACYCLICS INC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Feb, 2034
(11 years from now) | |
|
US9296753
(Pediatric) | PHARMACYCLICS INC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Apr, 2034
(11 years from now) | |
| US9795604 | PHARMACYCLICS INC | Methods of treating and preventing graft versus host disease |
Oct, 2034
(11 years from now) | |
| US10695350 | PHARMACYCLICS INC | Methods of treating and preventing graft versus host disease |
Oct, 2034
(11 years from now) | |
| US10463668 | PHARMACYCLICS INC | Methods of treating and preventing graft versus host disease |
Oct, 2034
(11 years from now) | |
|
US9795604
(Pediatric) | PHARMACYCLICS INC | Methods of treating and preventing graft versus host disease |
Apr, 2035
(12 years from now) | |
|
US10695350
(Pediatric) | PHARMACYCLICS INC | Methods of treating and preventing graft versus host disease |
Apr, 2035
(12 years from now) | |
|
US10463668
(Pediatric) | PHARMACYCLICS INC | Methods of treating and preventing graft versus host disease |
Apr, 2035
(12 years from now) | |
| US9655857 | PHARMACYCLICS INC | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor |
Mar, 2036
(13 years from now) | |
| US10010507 | PHARMACYCLICS INC | Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor |
Mar, 2036
(13 years from now) | |
| US10213386 | PHARMACYCLICS INC | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor |
Mar, 2036
(13 years from now) | |
| US10828259 | PHARMACYCLICS INC | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor |
Mar, 2036
(13 years from now) | |
|
US10010507
(Pediatric) | PHARMACYCLICS INC | Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor |
Sep, 2036
(13 years from now) | |
|
US10828259
(Pediatric) | PHARMACYCLICS INC | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor |
Sep, 2036
(13 years from now) | |
|
US9655857
(Pediatric) | PHARMACYCLICS INC | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor |
Sep, 2036
(13 years from now) | |
|
US10213386
(Pediatric) | PHARMACYCLICS INC | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor |
Sep, 2036
(13 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| M | Jan 25, 2022 |
| New Patient Population (NPP) | Aug 24, 2025 |
| Orphan Drug Exclusivity (ODE) | Aug 2, 2024 |
| Pediatric Exclusivity (PED) | Feb 24, 2026 |
Market Authorisation Date: 13 November, 2013
Treatment: Treatment of small lymphocytic lymphoma; Treatment of chronic lymphocytic leukemia with 17p deletion; Treatment of small lymphocytic lymphoma with 17p deletion; Treatment of mantle cell lymphoma; Treatment of marginal zone lymphoma; Treatment of chronic lymphocytic leukemia; Treatment of waldenstrom's macroglobulinemia; Treatment of pediatric patients age 1 year and older with chronic graft-versus-host disease (cgvhd) after failure of one or more lines of systemic therapy; Treatment of relapsed or refractory small lymphocytic lymphoma; Treatment of relapsed or refractory chronic lymphocytic leukemia; Treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma; Treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma with 17p deletion; For the treatment of patients with waldenstrom's macroglobulinemia; Treatment of chronic graft versus host disease refractory to systemic therapy; Treatment of refractory chronic graft-versus-host disease
Dosage: CAPSULE;ORAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic